Cutler Group LP Celldex Therapeutics, Inc. Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	SELL	$22.61 - $40.65 $904 - $1,626	-40 Reduced 2.67%	1,460 $57,000
Q3 2023 Nov 07, 2023	SELL	$25.45 - $37.46 $10,180 - $14,984	-400 Reduced 21.05%	1,500 $41,000
Q2 2023 Jul 18, 2023	BUY	$30.29 - $38.28 $36,348 - $45,936	1,200 Added 171.43%	1,900 $64,000
Q1 2023 May 01, 2023	SELL	$34.78 - $47.43 $4,625 - $6,308	-133 Reduced 15.97%	700 $25,000
Q4 2022 Feb 07, 2023	BUY	$27.78 - $45.38 $277 - $453	10 Added 1.22%	833 $37,000
Q3 2022 Oct 25, 2022	BUY	$22.7 - $37.57 $18,682 - $30,920	823 New	823 $23,000
Q1 2022 Apr 14, 2022	SELL	$27.64 - $39.32 $152,020 - $216,260	-5,500 Reduced 72.37%	2,100 $71,000
Q4 2021 Jan 18, 2022	SELL	$35.68 - $56.27 $67,792 - $106,913	-1,900 Reduced 20.0%	7,600 $293,000
Q3 2021 Oct 26, 2021	BUY	$28.95 - $55.99 $92,640 - $179,168	3,200 Added 50.79%	9,500 $512,000
Q2 2021 Jul 19, 2021	BUY	$20.71 - $35.37 $130,473 - $222,830	6,300 New	6,300 $210,000

206

70.2M

1.46M

868K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.06B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.